Duesseldorf, April 30, 2015 – At its meeting following today’s Annual General Meeting, the Supervisory Board of Gerresheimer AG elected Dr. Axel Herberg (57) as the new Chairman of the Supervisory Board. His longstanding predecessor as Chairman of the Supervisory Board, Gerhard Schulze (70), today stepped down for reasons of age in accordance with the Articles of Association.
“In Dr. Axel Herberg, we have gained an excellent Chairman of the Supervisory Board who previously demonstrated his strategic acumen in his ten years as Chief Executive Officer of Gerresheimer AG. This will be to the benefit of the Company in his new role,” said Gerhard Schulze, the outgoing Chairman of the Supervisory Board of Gerresheimer AG.
Dr. Axel Herberg (57) gained his doctorate in economics. He joined the Gerresheimer Group in 1992. Dr. Herberg was Member of the Management Board from 1996 and Chief Executive Officer from 2000 to 2010. Since 2010, he has been Senior Managing Director of The Blackstone Group Germany GmbH, where he is responsible for the Blackstone Group’s private equity business in German-speaking regions of Europe. He has been a Member of the Supervisory Board of Gerresheimer AG since 2014.
“I would like to thank Mr. Schulze for his highly successful work for Gerresheimer. Mr. Schulze had a key part in shaping the development and the success of the Gerresheimer Group for 20 years as Member of the Management Board and in the last seven years as Chairman of the Supervisory Board,” said Dr. Axel Herberg, the new Chairman of the Supervisory Board of Gerresheimer AG.
Gerhard Schulze (70) joined the then Gerresheimer Glas AG in 1968 and was Member of the Management Board from 1985 to 2004. Mr. Schulze was Chairman of the Supervisory Board of Gerresheimer AG from February 2008.
Gerresheimer is a leading global partner to the pharma and healthcare industries. The company’s special glass and plastic products contribute to health and well-being. Gerresheimer is a global organization with 11,000 employees and manufacturing operations in the local markets, close to customers. It has over 40 production facilities in Europe, North and South America and Asia generating revenue in excess of EUR 1.3 billion. The comprehensive product portfolio includes pharmaceutical packaging products as well as convenient and safe drug-delivery systems such as insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products.